TWO COMPONENT STRATEGY FOR IMMUNE TARGETING

描述：(改编自调查人员的摘要)瞄准 抗原提呈细胞(APC)免疫原能显著增强T细胞 分别在体外和体内激活和产生抗体， 消除对传统佐剂的需求。这项提案的重点是 生物素结合FCG受体I(APC)特异性靶向的研究 连接到生物素化功能元件的元件(破伤风毒素C- 片段)。抗FCG受体I(FcgRI)-C片段的能力 体外和体内增强T细胞活化的结合物将是 通过监测T细胞增殖和细胞因子的产生而得到证实。 这种结合物在体内增强抗体产生的能力将 使用人FcgRI转基因小鼠进行评估，该小鼠表现出细胞 FcgRI的分布和密度与人类相似。跟随 抗FcgRI-C片段结合物免疫转基因小鼠的研究 结合物的生物分布，以及对它的抗体产生， 它的成分将使用放射性标记和酶联免疫吸附试验进行监测 技术，分别。 这种免疫靶向的两组分方法承诺是安全的， 用途极其广泛，性价比也很高。此外，它还将促进 多靶点、抗原和佐剂的快速评估和使用 组合，显著进步，可能是革命性的， 目前的疫苗技术。 建议的商业应用：不可用

DESCRIPTION: (Adapted from the investigator's abstract) Targeting immunogens to antigen presenting cells (APC) significantly enhances T cell activation and antibody production in vitro and in vivo, respectively, eliminating the need for traditional adjuvants. This proposal focuses on developing a biotin-binding Fcg receptor I (APC)-specific targeting element linked to a biotinylated functional element (tetanus toxin C- fragment). The ability of this anti-Fcg receptor I (FcgRI)-C-fragment conjugate to enhance T cell activation in vitro and in vivo will be demonstrated by monitoring T cell proliferation and cytokine production. The ability of this conjugate to enhance antibody production in vivo will be evaluated using human FcgRI transgenic mice which exhibit a cellular distribution and density of FcgRI similar to that in humans. Following immunization of transgenic mice with the anti-FcgRI-C-fragment conjugate, biodistribution of the conjugate, as well as antibody production to it, and its components will be monitored using radiolabeling and ELISA techniques, respectively. This two component approach to immune targeting promises to be safe, extremely versatile, and cost effective. In addition, it will facilitate the rapid evaluation and use of multiple targeting, antigen, and adjuvant combinations, significantly advancing, and possibly revolutionizing, current vaccine technology. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE